Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Shein Targets $26B-$27B Valuation for Hong Kong IPO 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
Add as a preferred source on Google
The US Justice Department charged Israeli generic drug firm Teva for conspiring to price-fixing, rigging bids, and allocating customers for generic drugs between 2013 and 2015.
The alleged transgressions caused patients to overpay by over $350 million.
Among the generic drugs was the cholesterol-regulating Pravastatin.
Teva, which sold $17 billion worth of drugs last year, rejected the charges saying it was “deeply disappointed" that the government proceeded with the prosecution.
It added that the US was unwilling to consider alternatives that would not be as impactful.
Five companies investigated in the case, including Sandoz, Taro, and Apotex have already paid fines to avoid prosecution.
Sandoz paid $195 million in March, while Apotex agreed to a $24.1 million fine in May.
In July, the American subsidiary of Israel's Taro Pharmaceuticals paid $205.7 million.
Earlier this month, Teva was also accused of inflating the reimbursement price for its multiple sclerosis drug, Copaxone, for patients in the Medicare program.
